Radius Health, Inc.

Transaction adds TYMLOS to portfolio alongside NUZYRA and XHANCE and creates a diversified portfolio expected to generate nearly $1 billion in revenue in 2026 KING OF PRUSSIA, Pa., March 18, 2026 - Paratek Pharmaceuticals, Inc., a privately held pharmaceu

Radius Health announced B-FLEXION Life Sciences has agreed to acquire the remaining 57% interest in the specialty biopharmaceutical company, purchasing shares currently held by affiliates of Patient Square Capital and Webster Equity Partners.

Transaction follows three years of accelerated growth and successful operations under B-FLEXION and Patient Square's ownership. Boston, MA, January 12, 2026 - Radius Health ("Radius" or "the Company"), a specialty biopharmaceutical company dedicated to bo

BOSTON, MA/ July 31, 2025 - Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused on bone health and related areas, announced today that the U.S. District

BOSTON, MA/ January 2, 2025 - Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused on bone health and related areas, announced today it has granted Pharma

BOSTON, MA/ December 9, 2024 - Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused on bone health and related areas, announced today it has granted Thera

BOSTON, MA/ June 25, 2024 - Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused on bone health and related areas, announced the appointment of Renata Skl

TYMLOS demonstrated a lower incidence of hip fracture and non-vertebral fracture compared to teriparatide in women with osteoporosis 50 years and older (n=43,352) in this analysis of real-world data BOSTON, MA/ April 16, 2024 - Radius Pharmaceuticals, Inc

BOSTON, MA, SEPTEMBER 26, 2023--(BUSINESS WIRE)--Radius Pharmaceuticals, Inc., a wholly owned subsidiary of Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceutical company focused on bone health and related areas, announced today th

BINOSTO (alendronate sodium) effervescent tablet complements currently marketed product, TYMLOS (abaloparatide) injection, for the treatment of Osteoporosis BOSTON--(BUSINESS WIRE)--Radius Health, Inc. ("Radius" or the "Company"), a specialty biopharmaceu